DOCSLIB.ORG

Novadaq Technologies, Inc. Healthcare- Dia G Nostic Ima G in G June 22, 2012 Company Description: Novadaq Technologies, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novadaq Technologies, Inc. Healthcare- Dia G Nostic Ima G in G June 22, 2012 Company Description: Novadaq Technologies, Inc Feltl and Company Research Department 2100 LaSalle Plaza 800 LaSalle Avenue Minneapolis, MN 55402 1.866.655.3431 Ben C. Haynor, CFA [email protected] | 612.492.8872 Novadaq Technologies, Inc. Healthcare- Dia g nostic Ima g in g June 22, 2012 Company Description: Novadaq Technologies, Inc. develops, manufactures and markets real-time fluorescence imaging products used by surgeons in open, minimally invasive and interventional surgical procedures to visualize blood flow and assess the quality of blood perfusion. The company was founded in 2000 and is based in Mississauga, Ontario, Canada. SPY no longer a secret, initiating with STRONG BUY, $8.50 PT (NVDQ - $5.57) STRONG BUY Key Points Financial Summary Novadaq’s proprietary SPY imaging technology revolutionizes blood flow and perfusion assessment. SPY imaging has broad applicability and a potential US consumable revenue opportunity of ~$1.8 billion. Rev(mil) 2011A 2012E 2013E Mar $2.6A $4.8A $8.2E Partnerships with industry leaders validate the strength June $3.6A $4.7E $9.6E of the company’s FDA-approved technology, while Sept $4.3A $5.7E $11.1E Novadaq retains a highly attractive market for itself. Dec $5.0A $7.8E $13.0E Potential “arms race” developing. FY $15.3A $23.0E $41.8E Initiating with STRONG BUY rating and $8.50 price P/Sales 14.5x 9.6x 5.3x target (7.0x 2013 EV/Sales). Novadaq’s proprietary SPY imaging technology revolutionizes blood flow and perfusion assessment. Their unique technology allows surgeons to visualize blood flow and perfusion in real-time, which greatly enhances the ability to make proper clinical decisions during surgeries. For example, in breast reconstruction surgery and EPS 2011A 2012E 2013E gastrointestinal surgery, which typically register complication rates of over 12%, SPY imaging has been shown to reduce complication rates to 4% or less. The cost of Mar ($0.09)A ($0.14)A ($0.02)E complications that occur in these types of complex surgeries can run well into the six- June ($0.13)A ($0.00)E ($0.02)E figures and be devastating to patient outcomes. Over 50 peer-reviewed publications Sept ($0.04)A ($0.03)E ($0.00)E Dec ($0.06)A ($0.02)E $0.02E support the use of SPY imaging. The company’s SPY imaging technology has broad applicability, with current and FY ($0.32)A ($0.17)E ($0.02)E potential applications in plastic and reconstructive, gastrointestinal, cardiac, P/E NM NM NM cancer, and vascular surgeries (including wound care). We estimate the theoretical addressable market in the US to comprise well over one million procedures per year totaling roughly $1.8 billion in potential consumable sales. Novadaq has partnered with industry leaders, validating the strength of its technology platform, while reserving a highly attractive market for itself. The Price: $5.57 company has formed partnerships with Intuitive Surgical (ISRG – not rated), KCI, 52-Week Range: $7.98-$3.53 LifeCell, and MAQUET Cardiovascular for sales, marketing, and distribution. Each Target: $8.50 company they have partnered with is the market leader in the respective area covered Rating: STRONG BUY by the partnership, yet Novadaq has retained the endoscopic fluorescence imaging market for itself with its FDA-approved PINPOINT system, which will launch in the Shares Outstanding: 39.8 mil second half of this year. We believe the potential recurring revenue for PINPOINT in the Mkt. Capitalization: $222mil US market is ~$400 million per annum. Ave. Volume: 50,000 Instit. Ownership: 24% Due to the fact that SPY imaging is mainly used in complex surgeries (generally BV / Share: $0.8 costing more than $25,000), which are often the most profitable for hospitals, Debt / Tot. Cap.: 12% there is the potential for an “arms race” to develop amongst hospitals in a given Est. LT EPS Growth: 40% locale, whereby one hospital acquires a SPY imaging device causing the complex surgeries in the area to relocate to that hospital and forcing the other hospitals in the locale to purchase the technology as well. This is a similar situation to that which occurred with Intuitive Surgical’s da Vinci surgical robot. Our channel checks suggest this happened early this year in the Twin Cities market, and management has noted that they have seen the same occurrence elsewhere. Initiating coverage of Novadaq with a STRONG BUY rating and $8.50 price target, which represents 7.0x 2013 EV/Sales. Please see important disclosures on pages 20 to 22. June 22, 2012 rops Strong, Pricing Weak, Farm Profits Could Suffer INVESTMENT THESIS Novadaq offers a unique technology with its SPY imaging; no other technology on the market captures real-time blood flow and perfusion. The company’s technology show incredible promise in improving outcomes and lowering costs and has over 50 clinical publications supporting its use. At present, their solutions are most often used in complex surgical procedures, such as breast reconstruction, that are both expensive and suffer from high complication rates. Complications that develop in these types of procedures generally result in long and expensive hospital stays, which Novadaq’s imaging platform has been shown to drastically reduce, saving hospitals a great deal of time and money. We believe the potential US markets that can be served by Novadaq’s technology total ~$1.8 billion annually and have a compelling need for their products. In addition, it is a green-field opportunity that seldom arises so starkly. As such, we have assigned Novadaq a STRONG BUY rating and $8.50 price target. Opportunities Unique imaging modality with strong intellectual property position. Novadaq faces no direct competition from alternative fluorescent angiography systems currently and has a solid intellectual property foundation consisting of 49 patent families representing 52 granted or allowed patents and nearly 80 patent applications. Further, we are unaware of any potential competition on the horizon. Evidence of superior outcomes and cost savings. The large expenses in the healthcare system are usually generated by hospitalizations and the resulting length of stay. Novadaq’s SPY technology helps improve outcomes and save money by avoiding unnecessarily long hospital stays due to complications. The fact that the company’s products are presently used primarily in complex surgeries (read “expensive”) heightens the potential savings. Numerous studies (over 50) have validated both the superior outcomes and cost savings that result from the application of SPY imaging. Enviable partnerships with market leaders, yet Novadaq retains a highly attractive market for itself. Novadaq has formed partnerships with leading companies, including KCI, LifeCell, Intuitive Surgical (ISRG – not rated), and MAQUET Cardiovascular. Each company Novadaq has partnered with is a leader in their respective market; we believe this validates Novadaq’s technology and should serve to accelerate adoption of their products as Novadaq’s partners sell into their already well established sales channels. Importantly, Novadaq has retained the endoscopic fluorescence imaging market for itself with their FDA-approved PINPOINT system, which will launch in the second half of this year. We believe the potential recurring revenue for PINPOINT is ~$400 million per annum in the US market. Hospitals and surgeons beginning to accept Novadaq’s technology. When Novadaq first launched their SPY imaging platform with LifeCell, approximately 80% of the systems were placed in hospitals for evaluation prior to a permanent placement being agreed upon. Now, hospitals accept a permanent placement 80% to 90% of the time without requiring an evaluation. Additionally, Novadaq’s SPY imaging platform is in over 90% of the top 50 cancer surgery hospitals in the US. That said the company has installed systems in just over 400 hospitals to date, or ~12% of US hospitals with over 200 beds. This, to us, signals that leading hospitals view the technology as proven, but placements are still in the early-adopter phase with plenty of room to grow. Surgeons we have spoken to have noted that it improves on clinical judgment and SPY imaging has virtually no learning curve to using (“easier to use than an operating microscope”). Potential arms race developing. Due to the fact that SPY imaging is mainly used in complex surgeries, which are often the most profitable for hospitals (especially when complications can be successfully reduced), there is the potential for an “arms race” to develop amongst hospitals in a given locale, whereby one hospital acquires a SPY imaging device and the complex surgeries in the area relocate to that hospital, forcing the other hospitals in the locale to purchase the technology as well. This is a similar situation to that which occurred with Intuitive Surgical’s da Vinci surgical robot. Our channel checks suggest this happened early this year in the Twin Cities market, and management has noted that they have seen the same occurrence elsewhere. Broad application potential. Novadaq’s SPY technology is applicable to numerous types of procedures in open and minimally invasive surgeries. SPY imaging has been used in reconstructive, gastrointestinal (GI), cardiac, cancer and robotic surgeries. We estimate the US recurring revenue opportunity sums to ~$1.8 billion per year. Feltl and Company Research Department Novadaq Technologies, Inc. (NVDQ) Page 2 June 22, 2012 rops Strong, Pricing Weak, Farm Profits Could Suffer Risks Potential challenges of selling direct. The company plans to sell the PINPOINT product direct and has indicated that they would start out modestly with ten or so salespeople, and that they would scale up to 80-100 salespeople over time as the sales strategy is proven. Should the sales force struggle at first, Novadaq may slow down the addition of new salespeople and experience slower growth as a result. However, we believe this risk is mitigated somewhat, as Novadaq has experience building sales forces in the past; prior to partnering on SPY and their CO2 Heart Laser system, the company built sales forces dedicated to selling the products then transferred its salespeople to the partner company once the partnership agreement was in place.
Load more

Recommended publications
  • Enterprise Imaging Enterprise Imaging by Definition
    Enterprise Imaging Enterprise Imaging by definition The basic idea of Enterprise Imaging is to take all data (which includes images, waveforms, reports and other patient data) and amalgamate it into one place , instead of the current system of data residing in numerous, disconnected departmental data silos. An Enterprise Imaging Platform (EIP) provides the reliable infrastructure , and integration points , on which the Enterprise Imaging strategies and initiatives can be based. At the center of an enterprise imaging platform is an Enterprise Image Repository , which provides standards-based image archive infrastructure and services for storing and retrieving DICOM and non-DICOM clinical imaging content A SMARTER WAY FORWARD Explosion of data… Imaging data has exploded 4X in the last decade 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Radiology XRAY Radiology CT Radiology MRI Mammography Mammography Tomo Cardiology Endoscopy Dermatlogy A SMARTER WAY FORWARD The Carestream Solution A SMARTER WAY FORWARD “Carestream PACS” A SMARTER WAY FORWARD Significant Changes Changes in 12.1 – 64-bit for larger datasets and server-side rendering – DICOM Structure broken down – Removed file-size limitation – IHE Enhancements • Support of FHIR, JSON – Vue Explorer (CCP GUI) • Integrated Vue Motion • Capture Portal • Enhanced APIs to image enable the EPR A SMARTER WAY FORWARD One Enterprise Platform .. The platform can perform 4 major workflow steps:- Capture – various modules that can easily acquire different data formats Manage – various modules
    [Show full text]
  • Imaging Informatics
    Imaging Informatics: From Ideas to Action at SIIM Session #217, February 23, 2017 Rasu Shrestha MD MBA, Chief Innovation Officer, UPMC | @RasuShrestha Paul Nagy PhD, Associate Professor of Radiology, Johns Hopkins University | @PGNagy 1 Speaker Introduction Paul Nagy, PhD, FSIIM Deputy Director, Johns Hopkins Medicine Technology Innovation Center Associate Professor of Radiology Johns Hopkins University Chair of SIIM 2 Conflict of Interest Paul Nagy, PhD, FSIIM Board of Directors, SIIM (Society for Imaging Informatics in Medicine) 3 Speaker Introduction Rasu Shrestha MD, MBA Chief Innovation Officer, UPMC Executive Vice President, UPMC Enterprises Treasurer of SIIM 4 Conflict of Interest Rasu Shrestha MD MBA Board of Directors, SIIM (Society for Imaging Informatics in Medicine) Founding Member Executive Advisory Program, GE Healthcare Editorial Board, Applied Radiology Advisory Board, KLAS Research Advisory Board, Peer60 Board, Pittsburgh Dataworks Board, Pittsburgh Venture Capital Association 5 Agenda Machine Learning Value-based meets imaging Introduction Imaging informatics Enterprise DICOM moves Imaging: The to the web HIMSS-SIIM collaborative 6 Learning Objectives • Identify recent advancements in the field of imaging informatics • Discuss the Machine Intelligence progress made in medical imaging • Describe the interoperability standards in medical imaging • Outline specific advancements to measure value in imaging 7 Where Imaging Science meets Data Science SIIM is an Interdisciplinary society of imaging technology leaders in partnership
    [Show full text]
  • Integrating Non-DICOM Images Using
    Integrating Non-DICOM Images Using XDS Session # 71, February 21, 2017 Dawn Cram, IT Enterprise Imaging Director, University of Miami Health System Brian Hart, VP R&D, Merge Healthcare, an IBM Company 1 Speaker Introduction Dawn Cram, RT(R)(M)(ARRT),CIIP Director, IT Enterprise Imaging University of Miami Health System 2 Speaker Introduction Brian Hart Vice President, Research and Development Merge Healthcare, an IBM Company 3 Conflict of Interest Disclosure Dawn Cram Has no real or apparent conflicts of interest to report. Brian Hart Employed by Merge Healthcare, an IBM company Has no real or apparent conflicts of interest to report. 4 Agenda • Objectives and STEPS • Overview of Non-DICOM, XDS and Actors • Innovation at University of Miami • Benefits, Risks and Opportunities • Next Steps • STEPS Value Summary 5 Learning Objectives • Analyze the technical data flow for integrating non-DICOM images using XDS • Explain scalability and flexibility inherent within build • Illustrate the workflow for encounters-based, non-DICOM images • Illustrate the workflow for orders-based, non-DICOM images • Recognize the standards and IHE profiles employed and future opportunities 6 HIMSS STEPS™ This presentation addresses the following HIMSS value STEPS™ Satisfaction improvements will be measured through increased provider satisfaction associated with availability of a holistic image record complimenting the electronic health record. Treatment and clinical improvements will be evidenced by improvements in continuity of care and reducing risks. Electronic
    [Show full text]
  • Visible Light Image for Endoscopy, Microscopy, and Photography
    1 2 3 4 5 6 7 Digital Imaging and Communications in Medicine (DICOM) 8 9 SUPPLEMENT 15: Visible Light Image for Endoscopy, Microscopy, and Photography 10 11 12 13 14 15 16 17 18 Prepared by: 19 20 DICOM Standards Committee, Working Group 13 21 1300 N. 17th Street 22 Rosslyn, Virginia 22209 USA 23 24 VERSION: Final Text (2 July 1999) Supplement 15: Visible Light Image Page: i 1 2 Table of Contents 3 Foreword ii 4 Scope and Field of Application............................................................................................................iii 5 Acknowledgment...............................................................................................................................iii 6 A.X VISIBLE LIGHT IMAGE INFORMATION OBJECT DEFINITIONS............................................1 7 A.X.1 VL Endoscopic Image Information Object Definition......................................................1 8 A.X.1.1VL Endoscopic Image IOD Description...................................................................1 9 A.X.1.2VL Endoscopic Image IOD Entity-Relationship Model..............................................1 10 A.X.1.3VL Endoscopic Image IOD Content Constraints......................................................1 11 A.X.1.3.1....Modality............................................................................................1 12 A.X.1.3.2....Acquisition Context Module...............................................................1 13 A.X.2 VL Microscopic Image Information Object Definition......................................................2
    [Show full text]
  • Technical Challenges of Enterprise Imaging: HIMSS-SIIM Collaborative White Paper
    J Digit Imaging (2016) 29:583–614 DOI 10.1007/s10278-016-9899-4 REVIEW PAPER Technical Challenges of Enterprise Imaging: HIMSS-SIIM Collaborative White Paper David A. Clunie1 & Don K. Dennison2 & Dawn Cram3 & Kenneth R. Persons4 & Mark D. Bronkalla5 & Henri “Rik” Primo6 Published online: 30 August 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract This white paper explores the technical challenges Enterprise imaging . Enterprise imaging platform . Enterprise and solutions for acquiring (capturing) and managing enter- Image Repository . Enterprise PACS . EXIF . FHIR . Image prise images, particularly those involving visible light appli- file format . Integrating the Healthcare Enterprise (IHE) . cations. The types of acquisition devices used for various Image compression . Image distribution . Interoperability . general-purpose photography and specialized applications in- Medical image sharing . Metadata . Migration . Multimedia . cluding dermatology, endoscopy, and anatomic pathology are PACS . PACS implementation . Photography . Vendor neutral reviewed. The formats and standards used, and the associated archive (VNA) . Visible light . Whole slide imaging . XDS . metadata requirements and communication protocols for XDS-I transfer and workflow are considered. Particular emphasis is placed on the importance of metadata capture in both order- and encounter-based workflow. The benefits of using DICOM to provide a standard means of recording and accessing both Scope metadata and image and video data are considered, as is the role of IHE and FHIR. This paper is one of a series of white papers on Enterprise Imaging developed by HIMSS-SIIM workgroups [1–6]. It focuses on describing and solving the technical challenges Keywords Anatomic pathology . Archive . Dermatology . of enterprise imaging, and does not dwell on the rationale Digital image management .
    [Show full text]
  • Certified Healthcare Enterprise Architect (CHEA) Requirements
    20121106 Certified Healthcare Enterprise Architect (CHEA) Requirements This document contains the detailed requirements for the certification of a CHEA, or Certified Healthcare Enterprise Architect. These requirements focus on the image enabling component of the EMR and how to implement and support it. The certification assumes that candidates have at least 5 years of prior experience and/or knowledge in the healthcare clinical and IT domain. A requirement for taking this certification exam is that the candidate has a CPEMS and either a CPSA or CPIA certification. The CHEA certification specifically does NOT address any generic IT knowledge, including networking components, basic clinical and/or knowledge about healthcare standards such as basic DICOM, HL7 and IHE as this knowledge should be acquired through experience and/or other preceding certifications. Learning objectives: The candidate will be able to function as part of an implementation team and/or manager to implement a Electronic Health Record system in a healthcare environment. He or she will be able to participate in the planning and scope definition process because the candidate will have a thorough understanding and knowledge of the architecture, the interfacing and use by the various users. Item: The candidate should be able to: Keywords: 1 Image enabling the EHR 1.1 Implementation of image enabling 1 Imaging characteristics Characterize the different image types and their parameters which matrix size, bit depth, spatial, contrast determine resolution, size, and their management
    [Show full text]
  • Managing Imaging Education of the Future
    Promoting Management and Leadership in Medical Imaging Volume 8 Issue 3 / 2008 July - Sept. ISSN = 1377-7629 RADIOLOGY • CARDIOLOGY • INTERVENTION • SURGERY • IT • MANAGEMENT • EUROPE • ECONOMY • TRENDS • TECHNOLOGY MANAGING IMAGING EDUCATION OF THE FUTURE Create a Culture Special Focus Market Your of Leadership on Ultrasound Radiology Services www.imagingmanagement.org Cover_IM_V8_I3.indd 2-3 19/05/08 16:47:19 Cover_IM_V8_I3.indd 4-5 19/05/08 16:47:22 EDITORIAL Dear readers, hopefully eager to develop those in the earlier stages of gestation. A key feature of this change is the in- uccessful business requires a variety of man- creased use of molecular imaging to evaluate func- agement skills, but one essential factor is to tion and changes at molecular level. This requires Sproject the business forward and evaluate fu- greater emphasis on physiology and cell biology in ture trends and technological advances both for the the early years of the curriculum and more focused product range and methods, and delivery of services. training in the latter years. Radiology is no different, and its success has been partly due to the far-sightedness of our predecessors This training must also recognise changes that are Prof. Iain McCall to embrace and develop many new and increasingly occurring in the delivery of imaging to the patient Editor-in-Chief sophisticated imaging modalities. and be geared up to adapt. The European working [email protected] time directive had a dramatic effect on training in Delivering these new imaging modalities as a service many countries by altering the work to training bal- to the patient, however, often requires a comprehen- ance and the availability of trainees to develop their sive change management process, of which education skills.
    [Show full text]
  • Safety and Feasibility of Activsighttm Laser Speckle Imaging in Visualization of Tissue Perfusion and Critical Structures in Human
    Safety and Feasibility of ActivSightTM Laser speckle imaging in visualization of tissue perfusion and critical structures in human SAFETY AND FEASIBILITY OF ACTIVSIGHTTM LASER SPECKLE IMAGING IN VISUALIZATION OF TISSUE PERFUSION AND CRITICAL STURCTURES IN HUMAN Principal Investigator: Erik Wilson MD1 Associate Investigators: Shinil Shah DO FACS Peter C W Kim MD CM, PhD 2 Investigational Device: ActivSightTM Laser Speckle Imaging Protocol #: ACF0032020 Device: Activ Surgical Inc. Laser Speckle Imaging System Version Date: July 1 2020, V12 1 University of Texas Houston Department of Surgery 2Activ Surgical Inc 840 Summer Street Suite 108 Boston, MA 02127 Phone: 617-333-8162 Ext 400 FAX: 617-9821-0208 E-mail: [email protected] IRB NUMBER: HSC-MS-20-0967 1 IRB APPROVAL DATE: 10/21/2020 Proprietary and Confidential Safety and Feasibility of ActivSightTM Laser speckle imaging in visualization of tissue perfusion and critical structures in human PRECIS Background: ● The integrity of vasculature and tissue perfusion at the operative site remains a critical local determinant in expectant tissue healing, avoiding complications and ensuring good clinical outcome. Today, the most commonly used method of assessing vascularity and tissue perfusion intraoperatively however continues to be a simple visual inspection of tissue by naked human eyes guided by recall and experience regardless of surgical approach, MIS or open. ● The currently available additional means of visualizing blood flow intraoperatively are limited to radiation-based fluoroscopy with X-ray contrast dye or contrast agent such as a fluorophore-based near infrared camera system. These approaches are suboptimal in effectiveness (non-real time, lacks objectivity and specificity), cumbersome to efficient workflow (need for contrast reagent preparation and injection, potential adverse allergic reactions, risk of radiation exposure and/or training requirement), and efficacious utility (need for large capital equipment, space and cost).
    [Show full text]
  • A Review of Imaging Techniques in Scientific Research/Clinical Diagnosis
    MOJ Anatomy & Physiology Review Article Open Access A review of imaging techniques in scientific research/clinical diagnosis Abstract Volume 6 Issue 5 - 2019 This paper is a review of the image techniques used in research and diagnosis as Abubakar Abubakar Umar,1 Shaibu appeared in the literature. There are different types of scientific research and diagnostic 2 imaging techniques, including Photography, Microscopy, Ultrasound, X-rays, Computed Mohammed Atabo 1Department of Veterinary Anatomy, Usmanu Danfodiyo Tomography (CT) scans, Magnetic Resonance Imaging (MRI) and Positron Emission University, Nigeria Tomography (PET). The type of imaging used depends on the part of the body the scientist 2Department of Animal Health and Production Technology, wants to see on an image, as well as the type of imaging that is readily available to the College of Agriculture and Animal Science, Nigeria patient. Over the years, medical imaging has become a vital part in the early detection, diagnosis and treatment of cancer and other diseases. In some cases medical imaging is Correspondence: Shaibu Mohammed Atabo, Department the first step in preventing the spread of cancer through early detection and in many cases of Animal Health and Production Technology, College of makes it possible to cure or eliminate the cancer. CT scan, MRI, Ultrasound and X-ray Agriculture and Animal Science, Bakura, Zamfara State, Nigeria, imaging are very important tools in the fight against several diseases. Medical imaging is Tel +234(0)8069728062, Email also used to build accurate computer models of the body systems, organs, tissues and cells which are used in teaching anatomy and physiology in the medical schools.
    [Show full text]
  • OSF Saint Francis Medical Center Expands Use of the Orpheus Clinical Media Platform to Improve Workflow
    OSF Saint Francis Medical Center Expands Use of the Orpheus Clinical Media Platform to Improve Workflow Expanded implementation of the Orpheus Clinical Media Platform in all GI rooms at OSF Saint Francis Medical Center improves workflow and eliminates manual processes. NEW YORK, NY., November 17, 2016 — global clinical media platform and video informatics company Orpheus Medical announced today the expanded use of its Orpheus Clinical Media Platform at the OSF Saint Francis Medical Center (part of OSF HealthCare). The partnership; which began in 2014 between Orpheus Medical and OSF Healthcare, involved 2 pulmonary labs and helped streamline OSF’s workflow in a major way. From a manual and time consuming, print-scan-upload based workflow to a fully digital, high-quality imaging and automated workflow that seamlessly integrates with McKesson’s Radiology™ and Epic’s electronic health record (EHR) platform. Immediate benefits to this expansion include a reduced documentation turnaround time from 2 days to mere seconds, and an increase adherence to the improved workflow. “The Orpheus system deployed seamlessly and was quickly adopted by the clinical staff. The applications are user friendly and easy to support. The clinical benefits were evident from day one with high quality images now available in PACS and within our EMR (Electronic Medical Record) system”, says Steve Kastelein, Manager of Enterprise Imaging at OSF. “Video is used regularly for patient engagement, consultation, and training and performance improvement. Within a few hours all six rooms were connected, tested and ready for ‘go live’ the following morning–real plug-and-play. By lunchtime the following day, clinicians were using modality worklist, recording video and taking snapshots and using Orpheus Web to access video and images anywhere in the hospital”, says Adam McKeever, working in Steve’s team and supporting the clinicians and the solution.
    [Show full text]
  • Orders- Versus Encounters-Based Image Capture: Implications Pre
    J Digit Imaging (2016) 29:559–566 DOI 10.1007/s10278-016-9888-7 Orders- Versus Encounters-Based Image Capture: Implications Pre- and Post-Procedure Workflow, Technical and Build Capabilities, Resulting, Analytics and Revenue Capture: HIMSS-SIIM Collaborative White Paper Dawn Cram1 & Christopher J. Roth2,3 & Alexander J. Towbin4 Published online: 14 July 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract The decision to implement an orders-based versus an Medicalphotography .XDS .XDS-i .Imagecapture .MWL . encounters-based imaging workflow poses various implications EHR . Enterprise archive . PACS . VNA . ECM to image capture and storage. The impacts include workflows before and after an imaging procedure, electronic health record build, technical infrastructure, analytics, resulting, and revenue. Introduction Orders-based workflows tend to favor some imaging specialties while others require an encounters-based approach. The intent Images are being captured with increased frequency across of this HIMSS-SIIM white paper is to offer lessons learned specialties outside of radiology and cardiology throughout from early adopting institutions to physician champions and medical enterprises, including dermatology, ophthalmology, informatics leadership developing strategic planning and oper- wound care, otolaryngology, and emergency departments ational rollouts for specialties capturing clinical multimedia. [1]. Secure, centralized, and efficient image storage and man- agement in these non-traditional environments is currently challenging [2–4]. Clumsy workflows proliferate across ac- Keywords Imaging . Enterprise imaging . Clinical quiring specialties [2, 5, 6]. In this paper, we identify benefits multimedia . Imaging workflow . Encounter . and challenges of defining the proposed categories of orders- Encounters-based . Orders-based . DICOM . non-DICOM .
    [Show full text]
  • Near-Infrared Imaging of Brain Tumors Using the Tumor Paint BLZ-100 to Achieve Near-Complete Resection of Brain Tumors
    See the corresponding editorial in this issue (E2). Neurosurg Focus 36 (2):E1, 2014 ©AANS, 2014 Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors PRAMOD V. BUTTE, M.B.B.S., PH.D.,1 ADAM MAMELAK, M.D.,1 JULIA PARRISH-NOVAK, PH.D.,2 DONIEL DRAZIN, M.D.,1 FARIS SHWEIKEH, B.S.,1 PALLAVI R. GAngALUM, PH.D.,1 ALEXANDRA CHEsnOKOVA, M.D.,1 JULIA Y. LJUBIMOVA, M.D., PH.D.,1 AND KEITH BLACK, M.D.1 1Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California; and 2Blaze Bioscience, Inc., Seattle, Washington Object. The intraoperative clear delineation between brain tumor and normal tissue in real time is required to ensure near-complete resection without damaging the nearby eloquent brain. Tumor Paint BLZ-100, a tumor ligand chlorotoxin (CTX) conjugated to indocyanine green (ICG), has shown potential to be a targeted contrast agent. There are many infrared imaging systems in use, but they are not optimized to the low concentration and amount of ICG. The authors present a novel proof-of-concept near-infrared (NIR) imaging system using a standard charge-coupled device (CCD) camera for visualizing low levels of ICG attached to the tumors. This system is small, inexpensive, and sensitive. The imaging system uses a narrow-band laser at 785 nm and a notch filter in front of the sensor at the band. The camera is a 2-CCD camera, which uses identical CCDs for both visible and NIR light. Methods. The NIR system is tested with serial dilution of BLZ-100 from 1 μM to 50 pM in 5% Intralipid solu- tion while the excitation energy is varied from 5 to 40 mW/cm2.
    [Show full text]